Is ICI-based therapy better than chemotherapy for metastatic NSCLC patients who develop EGFR-TKI resistance? A real-world investigation.

ABSTRACT: To evaluate the outcomes of immune checkpoint inhibitor (ICI)-based treatments versus classical chemotherapy for metastatic non-small cell lung cancer (NSCLC) patients who develop epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) resistance and to explore the population that may benefit from ICI-based therapy. All patients who had previously received EGFR-TKI therapy at two cancer centers in China and developed resistance to targeted therapies were included. Progression-free survival (PFS) and overall survival (OS) were utilized to evaluate the outcomes of the study cohort. A total of 132 patients were included. The median follow-up time for this cohort was 21.7 months (IQR, 14.8-28.8 months), calculated from the date of EGFR-TKI resistance. The median PFS and OS were 4

SUBMITTER: Cheng Y 

PROVIDER: S-EPMC9445807 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature